Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
Trial Reaches Milestone of Over 1000 Patients Screened Addition of New Interventions – Biohaven Pharmaceuticals’ Troriluzole and Vigeo Therapeutics’ VT1021 Planned Expansion of Trial to Include Sites in Europe and China LOS ANGELES--(BUSINESS WIRE)--Global Coalition for Adaptive Research (GCAR) today announced an update on the progress of GBM AGILE (Glioblastoma…